Daily pharma news is mostly second-hand aggregation. This post is the output of a pipeline that skips the aggregators and reads only first-hand sources: regulator databases, trial registries and company wire releases.
TL;DR — A small Python pipeline pulled 116 items from SEC EDGAR, openFDA, ClinicalTrials.gov and two wire feeds for Sep 10–September 17, 2026: 32 deal events, 25 FDA approvals and 12 Phase 2/3 readouts due within 90 days. Everything below is extracted heuristically — regex and keyword rules, no LLM — and every row links back to the original filing or press release.
Today’s Deals
| Company | Type | Upfront | Total (incl. milestones) | Source |
|---|---|---|---|---|
| Yarrow Bioscience, Inc. | license | undisclosed | $150M | filing / release |
| Connect Biopharma Holdings Ltd | collaboration | undisclosed | $99M | filing / release |
| Tempest Therapeutics, Inc. | license | undisclosed | undisclosed | filing / release |
| Roche / Dualitas | other | undisclosed | $1B | filing / release |
| Cardiff Oncology, Inc. | license | undisclosed | undisclosed | filing / release |
| Perspective Therapeutics, Inc. | collaboration | undisclosed | undisclosed | filing / release |
| Sling | other | undisclosed | $123M | filing / release |
| — | other | undisclosed | $100M | filing / release |
| — | other | undisclosed | $750M | filing / release |
| — | financing | undisclosed | $123M | filing / release |
Table 1: Deal events in the collection window, sorted by disclosed total value.
Deal-comp context: across 17 deals with disclosed values in the window, the median total is $180M; the largest is $150M (Yarrow Bioscience, Inc.). Milestone-heavy structures dominate, so headline totals overstate near-term cash.
Figure 1: Disclosed total deal values collected this window.
FDA & Approvals
| Product (sponsor) | Date | Link |
|---|---|---|
| EPINEPHRINE (Zydus Pharms) | 2026-09-14 | Drugs@FDA |
| IMDELLTRA (Amgen Inc) | 2026-09-11 | Drugs@FDA |
| LISDEXAMFETAMINE DIMESYLATE (Ascent Pharms Inc) | 2026-09-10 | Drugs@FDA |
| ASENAPINE MALEATE (Alembic) | 2026-09-10 | Drugs@FDA |
| SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (Rubicon Research) | 2026-09-10 | Drugs@FDA |
| ITRACONAZOLE (Apotex) | 2026-09-11 | Drugs@FDA |
| GABAPENTIN (Invagen Pharms) | 2026-09-11 | Drugs@FDA |
| COLISTIMETHATE SODIUM (Sagent Pharms Inc) | 2026-09-14 | Drugs@FDA |
Table 2: Approvals recorded in openFDA’s Drugs@FDA feed this window.
Readout Calendar
Table 3: Phase 2/3 studies on ClinicalTrials.gov with primary completion dates in the next 90 days (major sponsors prioritized, ranked by enrollment).
Sources
- Yarrow Bioscience, Inc. 8-K mentioning license agreement
- Connect Biopharma Holdings Ltd 8-K mentioning collaboration agreement
- Tempest Therapeutics, Inc. 8-K mentioning license agreement
- Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
- Cardiff Oncology, Inc. 8-K mentioning license agreement
- Perspective Therapeutics, Inc. 8-K mentioning collaboration agreement
- Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
- Bristol Myers scraps $100M Orum-partnered cancer drug
- GSK doubles down on Chimagen with $750M multiple myeloma wager
- Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
- Korsana Biosciences, Inc. 8-K mentioning license agreement
- Newly formed Jaguar acquires Afib device assets from J&J
- Novo partners with Orbis, deepening investment in oral peptide drugs
- SK pens $315M pact with fellow South Korean company for Parkinson’s prospect
- Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
All items above are drawn from first-hand public sources — SEC filings, trial registries, and company releases. The same source-first discipline is what I apply to LLM agents in regulated programming.